Breast Cancer

Phase III study of RSR13 initiated in women with brain metastases

Published in Cancer Weekly, March 9th, 2004

Allos Therapeutics, Inc., (ALTH) announced that it has launched a multicenter phase III randomized open label trial of RSR13 (efaproxiral) as an adjunct to whole brain radiation therapy for the treatment of brain metastases from breast cancer.

The study will seek to enroll approximately 360 patients at up to 50 cancer centers across North America.

On February 2, 2004, the U.S. Food and Drug Administration (FDA) accepted for priority review the company's New Drug Application (NDA) to market RSR13 as an adjunct to whole brain radiation therapy for the treatment of brain metastases from breast cancer. The FDA has established a target date of June 4,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-03-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry